Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Review of 12 studies (n=1,052) found that, compared to controls, umifenovir was associated with higher negative rate of PCR on day 14 (RR 1.27, 95% CI 1.04-1.55) however there was no difference in rate of fever or rate of hospital length of stay.

SPS commentary:

Authors state that there is no evidence to support the use of umifenovir for improving patient-important outcomes in patients with COVID-19.


Umifenovir is licensed in Russia and China as an antiviral treatment for influenza.


Journal of Medical Virology